Absent T Lymphocytes

Search Trials
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Status:
Unknown status
Last Changed:
Nov 14, 2017
First Changed:
Dec 11, 2012
Disease(s):
ALK-negative Anaplastic Large Cell Lymphoma
Intervention(s):
Cyclophosphamide 750mg/m2Vincristine 1.4mg/m2Doxorubicin 50mg/m2prednisone 60mg/m2ifosfamide 2000mg/m2pirarubicin 50mg/m2pirarubicin 25mg/m2Etoposide phosphate 100mg/m2methotrexate 1500mg/m2
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Status:
Active, not recruiting
Last Changed:
Mar 10, 2020
First Changed:
Aug 27, 2015
Disease(s):
Peripheral T-Cell Lymphoma
Intervention(s):
CEOP/IVE/GDP chemotherapy regimenCEOP chemotherapy regimen for 6 cycles
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Status:
Terminated
Last Changed:
Apr 21, 2020
First Changed:
Mar 9, 2017
Disease(s):
Blastic Plasmacytoid Dendritic Cell Neoplasm
Intervention(s):
Laboratory Biomarker AnalysisNivolumab
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Status:
Active, not recruiting
Last Changed:
Mar 15, 2018
First Changed:
Nov 1, 2012
Disease(s):
Peripheral T-cell Lymphoma NOS
Intervention(s):
CyclophosphamideGemcitabineDoxorubicinVincristinePrednisolonemethylprednisoloneCisplatin
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma
Status:
Active, not recruiting
Last Changed:
Jun 18, 2021
First Changed:
Sep 28, 2015
Disease(s):
Anaplastic Large Cell Lymphoma, ALK-Negative
Intervention(s):
Autologous Hematopoietic Stem Cell TransplantationCyclophosphamideDoxorubicin HydrochlorideEtoposideLaboratory Biomarker AnalysisLenalidomidePeripheral Blood Stem Cell TransplantationPrednisoneVincristine Sulfate

Connect. Empower. Inspire.